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Background: Activating mutations [internal tandem duplication (ITD)] or overexpression of the FMS-like tyrosine
kinase receptor-3 (FLT3) gene are associated with poor outcome in acute myeloid leukemia (AML) patients,
underscoring the need for novel therapeutic approaches. The natural product silvestrol has potent antitumor
activity in several malignancies, but its therapeutic impact on distinct molecular high-risk AML subsets remains to
be fully investigated. We examined here the preclinical activity of silvestrol in FLT3-ITD and FLT3 wild-type (wt) AML.
Methods: Silvestrol in vitro anti-leukemic activity was examined by colorimetric cell viability assay, colony-forming
and flow cytometry assays assessing growth inhibition and apoptosis, respectively. Pharmacological activity of
silvestrol on FLT3 mRNA translation, mRNA and protein expression was determined by RNA-immunoprecipitation,
qRT-PCR and immunoblot analyses, respectively. Silvestrol in vivo efficacy was investigated using MV4-11 leukemia-
engrafted mice.
Results: Silvestrol shows antileukemia activity at nanomolar concentrations both in FLT3-wt overexpressing (THP-1)
and FLT3-ITD (MV4-11) expressing AML cell lines (IC50 = 3.8 and 2.7 nM, respectively) and patients’ primary blasts
[IC50 = ~12 nM (FLT3-wt) and ~5 nM (FLT3-ITD)]. Silvestrol increased apoptosis (~4fold, P = 0.0001), and inhibited
colony-formation (100%, P < 0.0001) in primary blasts. Silvestrol efficiently inhibited FLT3 translation reducing FLT3
protein expression by 80–90% and decreased miR-155 levels (~60%), a frequently co-regulated onco-miR in FLT3-
ITD-positive AML. The median survival of silvestrol-treated vs vehicle-treated mice was 63 vs 29 days post-
engraftment, respectively (P < 0.0001).
Conclusions: Silvestrol exhibits significant in vivo and in vitro antileukemic activities in AML through a novel
mechanism resulting in inhibition of FLT3 and miR-155 expression. These encouraging results warrant a rapid
translation of silvestrol for clinical testing in AML.Background
Acute myeloid leukemia (AML) is one of the most com-
mon types of leukemia. Today, only 40% of younger (age
<60 years) and 10% of older (age ≥60 years) adults with
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reproduction in any medium, provided the orlong-term survival [1]. The outcome for high-risk pa-
tients who are treated with allogeneic stem cell trans-
plantation in first complete remission are encouraging,
but lack of suitable donors, presence of co-morbidities
and treatment-related toxicity and mortality has often
limited the application of this approach. Therefore, novel
therapeutic strategies that improve the currently poor
outcome in AML patients while demonstrating an opti-
mal toxicity index are highly needed.
Recurrent cytogenetics and molecular aberrations are
known to impact the prognosis of AML. Importantly,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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novel therapeutic targets. Gain-of-function mutations of
the tyrosine kinase (TK) receptor encoding gene FLT3
occur in approximately 30% of AML patients, and result
in constitutive TK activity and, in turn, increasing
growth and survival of leukemia blasts [2]. Of the FLT3
mutations, the internal tandem duplication (FLT3-ITD)
is associated with poorer outcome [3-8]. In addition,
overexpression of the FLT3-wt receptor and its ligand
(FL) occurs in a high percentage of AML and the subse-
quent autocrine stimulatory loop may contribute to the
pathogenesis and aggressiveness of the disease [9,10].
Therefore, investigating compounds that can inhibit
both mutant and overexpressed wild type FLT3 in AML
leukemia is warranted.
Smith et al. demonstrated that FLT3-ITD likely consti-
tutes a driver mutation in AML and therefore it may rep-
resent not only as a prognosticator but also a potential
therapeutic target [11]. Emerging small molecule inhibi-
tor compounds have been shown to interfere with the ab-
errant FLT3 TK activity and lead to arrest of leukemia
growth [6,12]. Unfortunately the clinical impact of these
compounds as single agents or in combination with
chemotherapy has not yet fulfilled the promise, likely be-
cause of their relatively low potency, lack of specificity
and the early onset of mechanisms of resistance [13-15].
This underscores the need for additional strategies that
effectively target aberrant FLT3 activity in AML blasts
and improve the currently poor survival rate in high-risk
patients with FLT3-driven AML.
Silvestrol is a cyclopenta[b]benzofuran rocaglate with a
unique dioxanyl ring-containing side chain [16,17]. It
was isolated from the Indonesian plant Aglaia foveolata,
structurally characterized, and tested for anti-tumor effi-
cacy [16]. Silvestrol showed activity against several solid
tumor cell lines [18-21] as well as primary chronic
lymphocytic leukemia cells at nanomolar concentrations,
and prolonged survival in a murine model of B cell acute
lymphoblastic leukemia [22]. More recently, silvestrol
was reported to have synergistic activity against AML cell
lines when combined with chemotherapy [23]. Pelletier
et al., demonstrated that silvestrol interferes with assem-
bly of the eIF4F translation complex by promoting an ab-
errant interaction between capped mRNA and eIF4A,
thus blocking protein synthesis at the initiation step
[21,24]. This inhibition of protein synthesis results in a
preferential depletion of proteins with short half-lives,
such as MCL1, to which leukemia and cancer cells may
be addicted and thrive on [22,24]. Therefore, we hypo-
thesize that silvestrol could also inhibit translation of
FLT3 mRNA and in turn downregulate the expression of
FLT3 and decrease aberrant tyrosine kinase in FLT3-
driven AML. Thus, we sought to examine the in vitro
and in vivo anti-leukemic and biological activity ofsilvestrol in FLT3-ITD or FLT3-wt overexpressing AML
cell lines and primary blasts.
Methods
Reagents
Silvestrol was kindly provided by Dr. A. Douglas
Kinghorn. PKC412 was purchased from LC Laboratories
(Woburn, MA, USA).
Cell lines and primary blasts
MV4-11 and THP-1 cells (ATCC, Manassas, VA) were cul-
tured in RPMI 1640 medium supplemented with 10% calf
serum. Blasts from AML patients were maintained in RPMI
1640 medium supplemented with 30% fetal bovine serum,
1% HEPES buffer, and 1× StemSpan CC100 (StemCell
Technologies, Vancouver, BC, Canada) containing IL-3,
IL-6, FLT3 ligand and SCF. All cells were incubated at 37°C
with 5% CO2. Patient AML blasts were obtained from
apheresis blood samples collected from patients treated at
the Ohio State University (OSU) and stored in the OSU
Leukemia Tissue Bank. Informed consent to use cells for
investigational studies was obtained from each patient
under an OSU Institutional Review Board-approved proto-
col, according to the Declaration of Helsinki. Authentica-
ting tests of these cell lines was done using monoclonal
antibodies and FLT3 mutational analysis.
Immunoblot analyses
Cells were suspended 30 min in 1 × lysis buffer (20 mM
Hepes, 150 mM NaCl, 0.1% NP40) containing protease
inhibitor cocktail III (Calbiochem, Darmstadt, Germany)
and lysate was recovered by centrifugation. Lysates were
separated using 4-20% SDS-PAGE and transferred to
PVDF membrane (GE Healthcare, Piscataway, NJ). Mem-
branes were blocked using 5% milk or BSA in 1 × TBS
with 0.1% Tween 20 (1 × TBS-T) for 1 hour at room
temperature with shaking, then incubated overnight at 4°C
in the following primary antibodies diluted in 1 ×TBS-T
with 5% milk or BSA: actin (Santa Cruz Biotechnology,
Santa Cruz CA), FLT3 (Cell Signaling, Danvers, MA), phos-
phorylated and total STAT5 (Cell Signaling), P65 antibody
(Billerica, MA). Membranes were washed using 1 × TBS-T,
incubated with HRP-conjugated secondary antibodies di-
luted in 1 ×TBS-T with 5% milk or BSA, washed, and
developed using ECL Western Blotting Detection re-
agents (GE Heathcare).
RNA immunoprecipitation (RIP), RNA extraction, Real-
Time RT-PCR
MV4-11 cells were treated with 50 nM silvestrol for 3 hour,
lysed (5 min) in 100 mM KCl, 5 mM MgCl2, 10 mM
HEPES [pH 7.0], 0.5% NP-40, 1 mM dithiothreitol (DTT),
100 units/ml RNase OUT (Invitrogen), 400 mM vanadyl-
ribonucleoside complex and protease inhibitors (Roche,
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−80°C. Anti-eIF4E antibody (cell signaling) and goat IgG
(Sigma, St. Louis, MO) were incubated with protein sephar-
ose A/agarose G-coupled beads overnight. Beads were sub-
sequently washed four times with 50 mM TRIS/HCl,
pH 7.0, 150 mM NaCl, 1 mM MgCl2, and 0.05% NP-40,
and twice after addition of 1 M urea. Precipitates were
digested with proteinase K (55°C), and eIF4E-associated
mRNAs were isolated using Trizol reagent (Invitrogen,
Grand Island, NY). cDNA was synthesized using Super-
Script III reagents (Invitrogen) and the TaqMan MicroRNA
Reverse Transcription Kit (Applied Biosystems, Foster City,
CA) according to the manufacturer’s instructions. Quanti-
tative Real-Time RT-PCR for FLT3 and PU.1 genes and
miR-155 and miR-34a expression was performed using
commercially available TaqMan Gene Expression Assay
primers and probes and the 7900HT Fast Real-Time PCR
System (Applied Biosystems). The comparative cycle
threshold (CT) method was used to determine the expres-
sion levels normalized by the internal control 18S for gene
expression.
Clonogenic and viability analysis
Methylcellulose clonogenic assays were carried out by
plating 2 × 104 primary blasts in 0.9% MethoCult (Stem
Cell Technologies). Colonies (>100 mm) from cell lines
and primary cells were scored 14 days later. Growth in-
hibition assays were performed. Briefly, 5.0 × 104 cells
were incubated in triplicate in a 96-well plate in the
presence or absence of the different concentrations of
silvestrol in a final volume of 100 μl for 24, 48 and 72 hours
at 37°C. Thereafter, 20 μl of the CellTiter 96W AQueous.
One Solution Reagent which contains tetrazolium com-
pound [3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an
electron coupling reagent (phenazine ethosulfate; PES)
(Promega, Madison WI) was added to each well. After
4 hours incubation at 37°C, the optical density at 490 nm
was measured. Cell viability was calculated with respect to
the control samples. At least three independent experi-
ments were performed.
Flow cytometry
For FLT3 detection, cells (5 × 105) were washed with
phosphate-buffered saline (PBS) and resuspended in 50 μl
binding buffer containing 5 μL FLT3 antibody (BD Biosci-
ences, Billerica, MA). After 15 min incubation, cells were
washed with PBS, resuspended in 400 μL flow buffer and
analyzed on a FACSCalibur cytometer (BD Biosciences). To
assess apoptosis, AML cells were incubated with 10, 30 and
50 nM silvestrol for 24 hours. Cells (5 × 105) were then
washed with PBS and resuspended in 50 μl binding buffer
containing 2 μL of annexin V-FITC stock (BioWhittaker,
Inc, Walkersville, MD) and 5 μL propidium iodide (PI) (BDBiosciences). After 20 min incubation, fluorescence was
quantified by flow cytometry on a FACSCalibur instrument.
MV4-11 xenograft murine model
This model was developed recently in our laboratory and
described previously [25]. Briefly, 4 ~ 6 week-old non-obese
diabetic severe combined immunodeficient gamma (NSG)
mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, The Jackson La-
boratory, Bar Harbor, ME) were intravenously (i.v) injected
via tail vein with 2 × 107 MV4-11 cells. Two months later,
the spleen mononuclear cells (MNCs) were isolated from
MV4-11-injected mice (1st-adapted MV4-11 cells in NSG
mice). The adapted spleen MNCs were injected into a new
cohort of NSG mice via tail vein. The loading dose of cells
was reduced to 50% in this second transplantation. About a
month later, the spleen MNC were isolated and a 3rd trans-
plantation was performed using 0.5 × 107 cells/mouse
spleen MNC from 2nd adapted NSG mice. The sequential
transplants were performed using 0.5 × 106 cells/mouse
spleen MNC from 3rd adapted NSG mice. This provides a
more aggressive and fast onset of AML-like disease, thereby
allows for rapid read-out of the experiment. Indeed, we ob-
served development of leukemia at only two weeks from in-
jection and a median survival of approximately 4 weeks
after engraftment of the adapted MV4-11 cells from the 3rd
transplant. The complete blood count and FACS analysis of
CD45 and FLT3 expression and cytospin were examined
weekly to monitor the progression of disease. All the exper-
iments were conducted in accordance with the institutional
guidelines for animal care and use.
Spleen cells (0.5 × 106) from MV4-11 transplanted NSG
mice were intravenously (iv) injected into NSG mice via tail
vein, and divided into groups for vehicle (hydroxypropyl
beta-cyclodextrin in 30% sterile water; N = 6) or silvestrol
(1.5 mg/kg in vehicle; N = 10) treatment. One control
mouse (no leukemia/no treatment) was also included. Two
to three weeks after engraftment, white blood count
(WBC) and FLT3 expression by flow cytometry were
assessed to confirm transplantation. Treatments with
silvestrol or vehicle were initiated 21 days after engraftment
(based on disease signs documented by WBC count and
FLT3 expression). Administration was by intraperitoneal in-
jection every 48 hours for up to three weeks or until eu-
thanasia criteria were met. Expected median survival of
untreated animals in this model is 28 days. Mice were
weighed daily and checked for signs of dehydration, dis-
comfort or toxicity. On day of administration, doses were
recalculated for each animal after weighing to maintain
1.5 mg/kg. For the pharmacodynamic study, 6 mice were
used (3 per group, vehicle and silvestrol). These mice were
given 3 doses of either vehicle or silvestrol; and 48 hours
following the third dose, spleens were isolated and mono-
nuclear cells obtained for immunoblotting assay. For patho-
logical examination, tissue sections from the liver, spleen
Figure 1 (See legend on next page.)
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Figure 1 Antileukemic activity of silvestrol in vitro: (a) MV4-11 cells were incubated with 5 to 160 nM silvestrol. Cell viability was evaluated by
a MTS assay at 24, 48 and 72 hours. (b) AML cell lines were incubated with 5 to 160 nM silvestrol, and viability was evaluated by a MTS assay
48 hours later. (c) AML primary cells unmutated FLT3 or with FLT3-ITD were incubated with 5 to 320 nM silvestrol. Cell viability was evaluated by
MTS assay 48 hours following treatment. (d) Colony forming ability in primary blasts from FLT3-ITD positive and negative AML patients treated
with 25 nM of silvestrol and scored 14 days later. (e) Primary blasts from FLT3-ITD positive and negative AML patients treated with 10, 30 and 50
nM of silvestrol for 48 hours and analyzed by annexin/PI flow cytometry. Values are presented as mean ± SEM.
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ded in paraffin blocks, and H&E stained.
Wright-Giemsa staining
Morphological signs of apoptosis were detected by
Wright-Giemsa staining. Smears of control and treated
cells were stained with Wright-Giemsa solution for
25 min, rinsed with distilled water and air dried. Cell
morphology was studied by light microscopy.
Results
Silvestrol antileukemia activity in AML cells
The antileukemia activity of silvestrol was first tested in
AML cell lines. MV4-11 cells are FLT3-ITD positive,
whereas THP-1 cells are negative for FLT3-ITD but express
robust levels of FLT3-wt. Silvestrol impacted leukemia
growth (measured by MTS) in a dose- (5 to 160 nM) and
time-dependent manner (Figure 1a). At 48 hours, IC50
values (concentration required to inhibit growth to 50% of
control) were 2.7 and 3.8 nM in MV4-11 and THP-1 cells,
respectively (Figure 1b and Table 1). Primary blasts from
three AML patients with FLT3-ITD and two AML patients
with FLT3-wt were treated with 5 to 320 nM silvestrol. A
dose-dependent decrease in proliferation was observed,
with IC50 values at 48 hours of 3.7, 4.9, and 6.4 nM for the
blasts from the FLT3-ITD patients (n = 3), 16.9 and 6.6 nM
for the blasts from the FLT3-wt patients (n = 2; Figure 1c
and Table 1). We also performed a colony forming assay of
silvestrol in primary samples from three of the five patients,
including two of the FLT3-ITD positive cases. We observed
no colony formation for any of the tested samples when
blasts were treated with 25 nM of silvestrol (Figure 1d).Table 1 Calculated IC50 values for AML cell lines and
primary blasts at 48 h
Cell line FLT3 status IC50 (95% Confidence intervals)
MV4-11 FLT3-ITD 2.65 nM (1.49 to 4.72)
THP-1 FLT3-wt 3.81 nM (2.46 to 5.09)
Primary blasts
Pat #1 FLT3-wt 16.9 nM (13.6 to 21.1)
Pat #2 FLT3-wt 6.61 nM (5.67 to 7.70)
Pat #3 FLT3-ITD 3.65 nM (2.21 to 6.04)
Pat #4 FLT3-ITD 4.89 nM (3.90 to 6.12)
Pat #5 FLT3-ITD 6.41 nM (4.07 to 10.1)To determine whether exposure to silvestrol resulted in
apoptosis, we utilized annexin and PI staining of cells
treated with 10–50 nM silvestrol for 48 hours. A dose-
dependent increase in apoptosis was observed in silvestrol
treated compared with vehicle-treated primary blasts from
FLT3-ITD (n = 3) as well as FLT3-wt (n = 2) AML pa-
tients (Figure 1e). In AML primary cells, silvestrol in-
duced 1 to 7.5 fold increase in apoptosis in both FLT3-wt
and FLT3-ITD blasts (P = 0.0001 for every tested case)
treated with 10, 30 and 50 nM of silvestrol compared
with vehicle treated controls.
Silvestrol downregulates FLT3 expression through
inhibition of FLT3 translation initiation
Silvestrol interferes with assembly of the eIF4F translation
complex by promoting an aberrant interaction between
capped mRNA and eIF4A, thus blocking protein synthesis
at the initiation step [21,24]. This inhibition of protein
synthesis results in a preferential depletion of proteins
with short half-lives to which leukemia and cancer cells
may be addicted [22,24]. However, whether silvestrol also
inhibits FLT3 initiation of translation resulting in inhi-
bition of FLT3 protein synthesis has not been reported.
Thus, using an RNA immunoprecipitation assay, we tes-
ted this possibility.
Because of the difficulty immunoprecipitating eIF4A pro-
tein for the RNA immunoprecipitation assay using com-
mercially available antibodies, we utilized an antibody
against eIF4E, a subunit of the initiation of translation com-
plex that binds the mRNA cap structure. To avoid the
interference due to cell death usually observed with more
prolonged drug exposure and at the same time to ensure
adequate pharmacologic activity, cells were exposed to
silvestrol at concentrations that were higher than the calcu-
lated in vitro IC50 but that were also achievable in vivo, and
harvested at 24 hours or earlier time points [26]. MV4-11
cells were treated with 50 nM silvestrol for 3 hours and
eIF4E was immunoprecipitated in three different experi-
ments. Associated RNA was then assessed for depletion of
FLT3 RNA by quantitative RT-PCR. While no change in
FLT3 mRNA levels was observed in total RNA from
MV4-11 cells treated with silvestrol compared with
vehicle-treated cells, a five-fold depletion of FLT3 mRNA
was detected in eIF4E immunoprecipitates from silvestrol-
treated cells compared with vehicle-treated cells at 3 hours
Figure 2 (See legend on next page.)
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Figure 2 Silvestrol down-regulates FLT3: (a) FLT3 mRNA expression in eIF4E immunoprecipitates from 50 nM silvestrol treated MV4-11 cells
compared with that from untreated cells. Values are presented as mean ± SEM. (b) Expression of FLT3 examined by flow cytometry in MV4-11 and
THP-1 cells after 24 hours exposure to 50 nM silvestrol. Blue = silvestrol-treated samples; Red = vehicle-treated control. (c) AML cells treated with
50 nM silvestrol and examined for FLT3 protein expression by immunoblotting. (d) MV4-11 cells treated with silvestrol or PKC412 (50 nM each) for
6 hours, and assessed for STAT5 phosphorylation by immunoblotting. (e) Primary AML cells incubated with increasing concentrations of silvestrol for
24 hours, and assessed for FLT3 protein expression by immunoblotting.
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FLT3 receptor expression (by flow cytometry) (Figure 2b)
and 92% and 84% reduction in FLT3-ITD or FLT3-wt pro-
tein levels (by western blot) respectively in MV4-11 and
THP-1 cells, exposed to 50 nM silvestrol for 24 hours,
compared with vehicle-treated controls (Figure 2c). Since
total FLT3 protein levels were almost undetectable follow-
ing silvestrol treatment, phosphorylated FLT3 was
expected with be depleted as well. Therefore, TK activity
was determined by measuring phosphorylation of the
FLT3 target protein STAT5 in MV4-11 cells, which was
found decreased following silvestrol treatment (Figure 2d).
Similarly, down-regulation of FLT3 protein was observed
in silvestrol-treated primary blasts (FLT3-wt and FLT3-
ITD) (Figure 2e).
Silvestrol downregulates miR-155 expression in FLT3-ITD
positive AML
MicroRNAs are short, non-coding RNA that disrupt
translation of mRNA targets, thereby resulting in down
regulation of the mRNA corresponding encoded pro-
teins. miR-155 has a known oncogenic activity in he-
matologic malignancies [27,28]. Sustained expression of
this miR in hematopoietic stem cells causes a myelopro-
liferative disorder [29]. We and others reported that
miR-155 is up-regulated in FLT3-ITD positive AML
compared with FLT3-wt AML, although whether this
microRNA directly contributes to the leukemogeneic ac-
tivity of FLT3-ITD is unknown [4,30,31]. Having shown
that silvestrol downregulated FLT3-ITD protein, next we
tested whether silvestrol also altered the expression of
miR-155 that appears co-regulated with FLT3. Thus,
miR-155 expression was measured in MV4-11 cells
treated with 50 nM of silvestrol by qRT-PCR. We found
approximately a 60% decrease in miR-155 expression in
silvestrol treated compared with untreated cells (P = 0.05),
while no significant change was observed in the expression
of an unrelated miRs (i.e., miR-34) (Figure 3a, b and c). In
order to examine the effect of silvestrol on miR-155 func-
tion, we treated MV4-11 cells with 50 nM silvestrol and
assessed the mRNA expression of the miR-155 target gene
PU.1 [32]. Twenty-four hours following treatment with
silvestrol, PU.1 expression showed about 2 folds increase
in the mRNA expression level compared with untreated
MV4-11 (P = 0.04) (Figure 3d). Similar results were
obtained in FLT3-ITD positive primary blasts; these cellsexhibited 60% decrease in miR-155 expression (P < 0.01)
and a 1.6-fold increase in PU.1 expression (P < 0.01), 24 -
hours following treatment with 50 nM of silvestrol com-
pared with untreated cells (Figure 3e and f).
The mechanisms through which constitutively acti-
vated FLT3 associates with increased miR-155 expression
are unknown. However, miR-155 has been reported to
be a target of NF-κB, which is also potentially activated
in AML blasts with constitutively activated FLT3 [33,34].
Additionally, Gerlof et al. reported that FLT3-ITD in-
duces the oncogenic miR-155 via STAT5 and NF-κB
(p65) [35]. Given that silvestrol belongs to the rocaglate
derivatives, which have been reported to inhibit the ac-
tivity of NF-κB [18,36], we then verified the effect of
silvestrol on NF-κB protein levels. When we treated
MV4-11 and THP-1 cells with 50 nM of silvestrol for
24 hours, we observed decrease in NF-κB (P65) protein
expression in silvestrol-treated cells compared with
vehicle-treated cells (Figure 3g). This suggests that
silvestrol may induce miR-155 downregulation likely
through direct inhibition of NF-κB (FLT3-ITD-negative
THP-1 cells), and indirect inhibition of NF-κB via
FLT3-ITD-dependent mechanisms (FLT3-ITD-positive
MV4-11 cells). Nevertheless, the compound effectively
targets both the microRNA and the mutant protein
that may concurrently contribute to the aggressiveness
of FLT3-ITD AML.
Activity of silvestrol in FLT3-ITD positive leukemia grafts
A MV4-11 leukemia graft murine model was employed
to investigate the in vivo efficacy of silvestrol in AML.
NSG mice were subjected to secondary transplant with
MV4-11 cells harvested from the spleen of previous
MV4-11 engrafted mice that developed an aggressive
AML-like disease. Twenty-one days post-engraftment,
mice were treated intraperitoneally with vehicle (Group
1) or 1.5 mg/kg silvestrol (Group 2) every other day for
3 weeks. The silvestrol dose and schedule used here
were previously reported for lymphoid leukemia models
[22,37]. Forty-eight hours following the first two doses,
blood samples with circulating MV4-11 cells were taken
from 3 mice from each group, and FLT3 expression was
assessed by flow cytometry. A two- and three-folds in-
crease in FLT3 expression was observed in vehicle-
treated mice 48 hours after the first (P = 0.07) and
second (P = 0.024) treatment doses compared with
Figure 3 (See legend on next page.)
Alachkar et al. Journal of Hematology & Oncology 2013, 6:21 Page 8 of 12
http://www.jhoonline.org/content/6/1/21
(See figure on previous page.)
Figure 3 Silvestrol down-regulates miR-155 and upregulates miR-155 target PU.1: (a) MV4-11 cells were treated with 50 nM of silvestrol and
miR-155 expression was measured and normalized to U44 expression at 6, 12 and 24 hours following silvestrol treatment.
(b) MV4-11 cells were treated with 50 nM of silvestrol for 24 hours, and miR-34a expression was measured thereafter. (c,d) MV4-11 cells
were treated with 50 nM of silvestrol for 24 hours, and miR-155 (c) and PU.1 expression (d) levels were measured thereafter. (e,f) FLT3-ITD
positive primary cells were treated with 50 nM of silvestrol for 24 hours, and miR-155 expression (e) and PU.1 expression (f) levels were
measured thereafter. (g) MV4-11 and THP-1 cells were treated with 50 nM of silvestrol for 24 hours and assessed for P65 protein
expression by immunoblotting. Values are presented as mean ± SEM.
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found in the silvestrol treatment group (Figure 4a). After 3
doses (day 6 of treatment), spleens from three mice from
each group were examined. Spleens from silvestrol treated
mice were 60% smaller (P = 0.016) (Figure 4b), and showed
an 80% reduction in FLT3 protein (P = 0.002) compared
with vehicle-treated controls (Figure 4c). Cytospins of bone
marrow cells and histopathology of bone marrow (ster-
num), spleen, and liver sections from MV4-11-engrafted
mice treated with vehicle showed extensive infiltration of
blast cells. In contrast, cytospins and histopathology from
silvestrol-treated leukemic mice were similar to those of
the age-matched control mice (Figure 4d, e). Silvestrol-
treated leukemic mice (n = 10) survived significantly lon-
ger than the vehicle-treated controls (n = 6) (median sur-
vival: 63 days from engraftment vs. 29 days, respectively;
P < 0.0001). All mice in the vehicle group died by day 31
from engraftment (day 11 from treatment start), while 50%
of silvestrol-treated mice were still alive on day 74 from en-
graftment (day 54 from treatment start) (Figure 4f). Of the
silvestrol-treated mice, 30% were still alive at 6 months
from experiment start day. When sacrificed, these survived
mice showed no signs of leukemia.
Discussion
The natural product silvestrol has been shown to inhibit
translation initiation by modulating the interaction of
capped mRNA with the RNA helicase eIF4A [24]. Proto-
oncogenes such as CCND1, MCL1, and MYC tend to
encode proteins with short half-lives, and are therefore
more dependent on active translation to maintain pro-
tein levels that support malignant cell growth and sur-
vival. Such factors and in turn cancer cells addicted to
them, are thus expected to be more sensitive to transla-
tion inhibition by silvestrol, as was recently reported
[21-23,37]. To our knowledge, the effect of silvestrol on
FLT3 expression has not been previously reported. Here
we report that silvestrol also inhibits FLT3 mRNA trans-
lation thereby causing depletion of the encoded on-
coprotein, inhibition of the protein’s aberrant tyrosine
kinase activity. Silvestrol caused growth arrest and apop-
tosis in AML cell lines and primary blasts treated at
nanomolar concentrations. These results therefore ex-
tend the list of the oncoproteins targeted by silvestrol
and support the antileukemia activity of this compound.Most importantly, we showed a remarkable in vivo
activity of silvestrol in a FLT3-ITD leukemia engraftment
model. Mice engrafted with adapted MV4-11 cells de-
veloped leukemia and had a median survival of only
4 weeks. Treatment with silvestrol had no obvious tox-
icity and lowered the FLT3 expression to undetectable
levels after administration of only three doses. Silvestrol
treatment significantly prolonged survival and even cured
approximately 30% of the animals, further reinforcing the
concept that pursuing suppression of the FLT3-ITD pro-
tein expression may be a valid therapeutic approach in
FLT3-driven AML. Recently, there has been an increased
interest in utilizing small molecule kinase inhibitors to tar-
get aberrant TK activity of FLT3 mutants that contribute
to leukemia growth and poor outcome in AML patients
[38]. Unfortunately, the lack of selectivity, inadequate
pharmacokinetics, and early onset of resistance resulted in
relatively disappointing outcomes with these agents [39,40].
Nevertheless, FLT3 down-regulation via siRNA has been
shown to result in growth inhibition and apoptosis in
FLT3-ITD-positive AML cells [33,41]. This implicates that
interfering not only with aberrant activity of this kinase but
also with FLT3 expression might be a useful therapeutic
strategy in AML. Thus, drugs like silvestrol, that have the
ability to decrease the expression of FLT3 may be clinically
useful in this distinct subset of AML addicted to the FLT3
aberrant TK activity.
Although activity of silvestrol on the FLT3 expression
was impressive, it is likely that silvestrol as a natural
product and an inhibitor of eIF4A has the ability to alter
the expression and activity of several other targets that
may contribute to the impairment of leukemia growth.
Nevertheless, the antileukemia activity of this natural
product may result favorable for those FLT3-driven mo-
lecular subsets of AML that are resistant to chemother-
apy and/or enzymatic kinase inhibitors. To this end, we
not only showed silvestrol-related FLT3 suppression, but
also downregulation of miR-155, an oncomiR whose
expression is likely regulated by NF-κB often found
constitutively activated in FLT3-driven AML [42,43].
This microRNA has been shown to be upregulated in
FLT3-ITD positive AML, and is thought to contribute to
leukemia growth and aggressiveness in these molecular
subsets of AML through downregulation of several tar-
gets including PU.1 [4,31,44]. Indeed, we showed that
Figure 4 (See legend on next page.)
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Figure 4 In vivo antileukemic activity of silvestrol in FLT3-ITD positive MV4-11 xenograft leukemia mouse model: (a) FLT3 expression by
flow cytometry evaluated 48 hours after 1st and 2nd doses. (b) Spleen size after 3 silvestrol doses (day 6 of treatment) (c) Immunoblot of FLT3
protein expression in spleens from silvestrol-treated mice and vehicle-treated controls. (d) Cytospins of bone marrow cells and (e) histopathology
of bone marrow (sternum), spleen, and liver from the silvestrol-treated and vehicle-treated leukemic mice and age-matched (non-leukemic)
control mice showing the infiltration of leukemic blasts in the vehicle treated and signs of differentiation in the silvestrol treated mice (see red
pointing arrows). Stain: H&E; magnifications, 400×. (f) Survival analysis of silvestrol-treated leukemic mice (N = 10) compared with the vehicle-
treated controls (N = 6). Values are presented as mean ± SEM.
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viously reported to inversely correlate with FLT3 levels
[45]. Thus, the dual activity of silvestrol on FLT3 and
miR-155 expression suggests that this compound may
represent a potentially valuable therapeutic approach to
this high-risk AML subset.
Conclusions
We showed that silvestrol is a compound with a potent
anti-leukemia activity in FLT3-driven AML. These results
thereby provide a novel therapeutic strategy in FLT3-driven
AML by a novel mechanism that is not based on the dis-
ruption of the aberrant tyrosine kinase activity through en-
zymatic TK inhibition, but rather it is effective via
translation inhibition of FLT3 mRNA. Given these and
other previously published findings [22,37], silvestrol is now
under preclinical development in the National Cancer Insti-
tute’s NExT Program for a rapid translation into the clinic.
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